Dr Mikhail N Kosiborod (Saint Luke's America Heart Institute, Kansas City, US) discusses the DEFINE-HF study - Dapagliflozin effects on biomarkers, symptoms and functional status in HFrEF patients with or without diabetes.
Filmed on site at EASD 2019 by Radcliffe Cardiology.